Afficher la notice abrégée

CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies

dc.rights.licenseopenen_US
dc.contributor.authorCABY, Fabienne
dc.contributor.authorGUIGUET, Marguerite
dc.contributor.authorWEISS, Laurence
dc.contributor.authorWINSTON, Alan
dc.contributor.authorMIRO, Jose M.
dc.contributor.authorKONOPNICKI, Deborah
dc.contributor.authorLE MOING, Vincent
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBONNET, Fabrice
dc.contributor.authorREISS, Peter
dc.contributor.authorMUSSINI, Cristina
dc.contributor.authorPOIZOT-MARTIN, Isabelle
dc.contributor.authorTAYLOR, Ninon
dc.contributor.authorSKOUTELIS, Athanasios
dc.contributor.authorMEYER, Laurence
dc.contributor.authorGOUJARD, Cecile
dc.contributor.authorBARTMEYER, Barbara
dc.contributor.authorBOESECKE, Christoph
dc.contributor.authorANTINORI, Andrea
dc.contributor.authorQUIROS-ROLDAN, Eugenia
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorWITTKOP, Linda
dc.contributor.authorFREDERIKSEN, Casper
dc.contributor.authorCASTAGNA, Antonella
dc.contributor.authorTHURNHEER, Maria Christine
dc.contributor.authorSVEDHEM, Veronica
dc.contributor.authorJOSE, Sophie
dc.contributor.authorCOSTAGLIOLA, Dominique
dc.contributor.authorMARY-KRAUSE, Murielle
dc.contributor.authorGRABAR, Sophie
dc.contributor.authorPROJECT WORKING GROUP FOR THE COLLABORATION OF OBSERVATIONAL, H. I. V. Epidemiological Research Europe In EuroCoord
dc.date.accessioned2021-09-29T14:56:30Z
dc.date.available2021-09-29T14:56:30Z
dc.date.issued2021-07-01
dc.identifier.issn1058-4838en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/112488
dc.description.abstractEnBACKGROUND: A persistently low CD4/CD8 ratio has been reported to inversely correlate with the risk of non-AIDS defining cancer in people living with human immunodeficiency virus (HIV; PLWH) efficiently treated by combination antiretroviral therapy (cART). We evaluated the impact of the CD4/CD8 ratio on the risk of Kaposi sarcoma (KS) or non-Hodgkin lymphoma (NHL), still among the most frequent cancers in treated PLWH. METHODS: PLWH from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) were included if they achieved virological control (viral load ≤ 500 copies/mL) within 9 months following cART and without previous KS/LNH diagnosis. Cox models were used to identify factors associated with KS or NHL risk, in all participants and those with CD4 ≥ 500/mm3 at virological control. We analyzed the CD4/CD8 ratio, CD4 count and CD8 count as time-dependent variables, using spline transformations. RESULTS: We included 56 708 PLWH, enrolled between 2000 and 2014. At virological control, the median (interquartile range [IQR]) CD4 count, CD8 count, and CD4/CD8 ratio were 414 (296-552)/mm3, 936 (670-1304)/mm3, and 0.43 (0.28-0.65), respectively. Overall, 221 KS and 187 NHL were diagnosed 9 (2-37) and 18 (7-42) months after virological control. Low CD4/CD8 ratios were associated with KS risk (hazard ratio [HR] = 2.02 [95% confidence interval {CI } = 1.23-3.31]) when comparing CD4/CD8 = 0.3 to CD4/CD8 = 1) but not with NHL risk. High CD8 counts were associated with higher NHL risk (HR = 3.14 [95% CI = 1.58-6.22]) when comparing CD8 = 3000/mm3 to CD8 = 1000/mm3). Similar results with increased associations were found in PLWH with CD4 ≥ 500/mm3 at virological control (HR = 3.27 [95% CI = 1.60-6.56] for KS; HR = 5.28 [95% CI = 2.17-12.83] for NHL). CONCLUSIONS: Low CD4/CD8 ratios and high CD8 counts despite effective cART were associated with increased KS/NHL risks respectively, especially when CD4 ≥ 500/mm3.
dc.language.isoENen_US
dc.subject.enKaposi sarcoma
dc.subject.enNon-Hodgkin lymphoma
dc.subject.enCD4/CD8 ratio
dc.subject.enCD8 T-cells
dc.subject.enEfficient cART
dc.title.enCD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/cid/ciaa1137en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34370842en_US
dc.description.sponsorshipEuropeEuropean Union Seventh Framework Programmeen_US
dc.description.sponsorshipEuropeEuropean Network of HIV/AIDS Cohort Studies to Coordinate at European and International Level Clinical Research on HIV/AIDSen_US
bordeaux.journalClinical Infectious Diseasesen_US
bordeaux.page50-59en_US
bordeaux.volume73en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamMORPH3Eusen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDAgence Nationale de Recherches sur le Sida et les Hépatites Viralesen_US
hal.identifierhal-03358925
hal.version1
hal.date.transferred2021-09-29T14:56:36Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Infectious%20Diseases&rft.date=2021-07-01&rft.volume=73&rft.issue=1&rft.spage=50-59&rft.epage=50-59&rft.eissn=1058-4838&rft.issn=1058-4838&rft.au=CABY,%20Fabienne&GUIGUET,%20Marguerite&WEISS,%20Laurence&WINSTON,%20Alan&MIRO,%20Jose%20M.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée